Research ExplorerPublicationsA new instrument for estimating the survival of patients wit...

A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer

Standard

A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer. / Rades, Dirk; Huttenlocher, Stefan; Bajrovic, Amira; Karstens, Johann H; Bartscht, Tobias.

In: RADIOTHER ONCOL, Vol. 49, No. 1, 03.2015, p. 86-90.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rades, D, Huttenlocher, S, Bajrovic, A, Karstens, JH & Bartscht, T 2015, 'A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer', RADIOTHER ONCOL, vol. 49, no. 1, pp. 86-90. https://doi.org/10.2478/raon-2014-0043

APA

Rades, D., Huttenlocher, S., Bajrovic, A., Karstens, J. H., & Bartscht, T. (2015). A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer. RADIOTHER ONCOL, 49(1), 86-90. https://doi.org/10.2478/raon-2014-0043

Vancouver

Rades D, Huttenlocher S, Bajrovic A, Karstens JH, Bartscht T. A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer. RADIOTHER ONCOL. 2015 Mar;49(1):86-90. https://doi.org/10.2478/raon-2014-0043

Bibtex

@article{d6a2d545e4014c1289e4769b7da46fa1,
title = "A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer",
abstract = "BACKGROUND: This study was initiated to create a predictive instrument for estimating the survival of patients with metastatic epidural spinal cord compression (MESCC) from esophageal cancer.METHODS: In 27 patients irradiated for MESCC from esophageal cancer, the following nine characteristics were evaluated for potential impact on survival: age, gender, Eastern Cooperative Oncology Group (ECOG) performance score, histology, number of involved vertebrae, ambulatory status before irradiation, further bone metastases, visceral metastases, and dynamic of developing motor deficits before irradiation. In addition, the impact of the radiation regimen was investigated. According to Bonferroni correction, p-values of < 0.006 were significant representing an alpha level of < 0.05.RESULTS: ECOG performance score (p < 0.001), number of involved vertebrae (p = 0.005), and visceral metastases (p = 0.004) had a significant impact on survival and were included in the predictive instrument. Scoring points for each characteristic were calculated by dividing the 6-months survival rates (in %) by 10. The prognostic score for each patient was obtained by adding the scoring points of the three characteristics. The prognostic scores were 4, 9, 10, 14 or 20 points. Three prognostic groups were formed, 4 points (n = 11), 9-14 points (n = 12) and 20 points (n = 4). The corresponding 6-months survival rates were 0%, 33% and 100%, respectively (p < 0.001). Median survival times were 1 month, 5 months and 16.5 months, respectively.CONCLUSIONS: This new instrument allows the physician estimate the 6-months survival probability of an individual patient presenting with MESCC from esophageal cancer. This is important to know for optimally personalizing the treatment of these patients.",
author = "Dirk Rades and Stefan Huttenlocher and Amira Bajrovic and Karstens, {Johann H} and Tobias Bartscht",
year = "2015",
month = mar,
doi = "10.2478/raon-2014-0043",
language = "English",
volume = "49",
pages = "86--90",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer

AU - Rades, Dirk

AU - Huttenlocher, Stefan

AU - Bajrovic, Amira

AU - Karstens, Johann H

AU - Bartscht, Tobias

PY - 2015/3

Y1 - 2015/3

N2 - BACKGROUND: This study was initiated to create a predictive instrument for estimating the survival of patients with metastatic epidural spinal cord compression (MESCC) from esophageal cancer.METHODS: In 27 patients irradiated for MESCC from esophageal cancer, the following nine characteristics were evaluated for potential impact on survival: age, gender, Eastern Cooperative Oncology Group (ECOG) performance score, histology, number of involved vertebrae, ambulatory status before irradiation, further bone metastases, visceral metastases, and dynamic of developing motor deficits before irradiation. In addition, the impact of the radiation regimen was investigated. According to Bonferroni correction, p-values of < 0.006 were significant representing an alpha level of < 0.05.RESULTS: ECOG performance score (p < 0.001), number of involved vertebrae (p = 0.005), and visceral metastases (p = 0.004) had a significant impact on survival and were included in the predictive instrument. Scoring points for each characteristic were calculated by dividing the 6-months survival rates (in %) by 10. The prognostic score for each patient was obtained by adding the scoring points of the three characteristics. The prognostic scores were 4, 9, 10, 14 or 20 points. Three prognostic groups were formed, 4 points (n = 11), 9-14 points (n = 12) and 20 points (n = 4). The corresponding 6-months survival rates were 0%, 33% and 100%, respectively (p < 0.001). Median survival times were 1 month, 5 months and 16.5 months, respectively.CONCLUSIONS: This new instrument allows the physician estimate the 6-months survival probability of an individual patient presenting with MESCC from esophageal cancer. This is important to know for optimally personalizing the treatment of these patients.

AB - BACKGROUND: This study was initiated to create a predictive instrument for estimating the survival of patients with metastatic epidural spinal cord compression (MESCC) from esophageal cancer.METHODS: In 27 patients irradiated for MESCC from esophageal cancer, the following nine characteristics were evaluated for potential impact on survival: age, gender, Eastern Cooperative Oncology Group (ECOG) performance score, histology, number of involved vertebrae, ambulatory status before irradiation, further bone metastases, visceral metastases, and dynamic of developing motor deficits before irradiation. In addition, the impact of the radiation regimen was investigated. According to Bonferroni correction, p-values of < 0.006 were significant representing an alpha level of < 0.05.RESULTS: ECOG performance score (p < 0.001), number of involved vertebrae (p = 0.005), and visceral metastases (p = 0.004) had a significant impact on survival and were included in the predictive instrument. Scoring points for each characteristic were calculated by dividing the 6-months survival rates (in %) by 10. The prognostic score for each patient was obtained by adding the scoring points of the three characteristics. The prognostic scores were 4, 9, 10, 14 or 20 points. Three prognostic groups were formed, 4 points (n = 11), 9-14 points (n = 12) and 20 points (n = 4). The corresponding 6-months survival rates were 0%, 33% and 100%, respectively (p < 0.001). Median survival times were 1 month, 5 months and 16.5 months, respectively.CONCLUSIONS: This new instrument allows the physician estimate the 6-months survival probability of an individual patient presenting with MESCC from esophageal cancer. This is important to know for optimally personalizing the treatment of these patients.

U2 - 10.2478/raon-2014-0043

DO - 10.2478/raon-2014-0043

M3 - SCORING: Journal article

C2 - 25810707

VL - 49

SP - 86

EP - 90

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

IS - 1

ER -